Treatment of recalcitrant atopic dermatitis with omalizumab

Journal of the American Academy of Dermatology

Volumn 54, Issue 1, 2006, Pages 68-72

  Lane, Joshua E ^a   Cheyney, Jason M ^a   Lane, Tanda N ^b   Kent, David E ^a   Cohen, David J ^a  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CETIRIZINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DIPHENHYDRAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; OMALIZUMAB; TACROLIMUS; TRIAMCINOLONE; ULOBETASOL PROPIONATE;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; PRIORITY JOURNAL; RECALCITRANT ATOPIC DERMATITIS; SCHOOL CHILD; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CHILD; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; TREATMENT OUTCOME;

EID: 29244441138     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.09.030     Document Type: Article

References (19)

1. J.M. Hanifin, and S. Chan Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies J Am Acad Dermatol 41 1999 72 77
2. D.Y.M. Leung, and N.A. Soter Cellular and immunologic mechanisms in atopic dermatitis J Am Acad Dermatol 44 Suppl 2001 S1 S12
3. G. Stingl IgE-mediated, Fc(epsilon)RI-dependent allergen presentation: a pathogenetic factor in atopic dermatitis? J Am Acad Dermatol 45 Suppl 2001 S17 S20
4. D.Y.M. Leung, E.E. Schneeberger, R.P. Siraganian, R.S. Geha, and A.K. Bhan The presence of IgE on monocytes, macrophages infiltrating the skin lesions of atopic dermatitis Clin Immunol Immunopathol 42 1987 328 337
5. R. Klubal, B. Osterhoff, B. Wang, J.P. Kinet, D. Maurer, and G. Stingl The high-affinity receptor for IgE is the predominant IgE-binding structure in lesional skin of atopic dermatitis patients J Invest Dermatol 108 1997 336 342
6. K.M. Leiferman A role for eosinophils in atopic dermatitis J Am Acad Dermatol 45 Suppl 2001 S21 S24
7. D. Maurer, E. Fiebiger, C.H. Ebner, B. Reininger, G.F. Fischer, and S. Wichlas Peripheral blood dendritic cells express FcεRI as a complex composed of FcεRIα- and FcεRhIλ-chains and can use this receptor IgE-mediated allergen presentation J Immunol 157 1996 607 616
8. D. Maurer, C.H. Ebner, B. Reininger, E. Fiebiger, D. Kraft, and J.P. Kinet The high affinity IgE receptor (FcεRI) mediates IgE-dependent allergen presentation J Immunol 154 1995 6285 6290
9. R. Valenta, D. Maurer, R. Steiner, S. Seiberler, W.R. Sperr, and P. Valent Immunoglobulin E response to human proteins in atopic patients J Invest Dermatol 107 1996 203 208
10. S. Natter, S. Seiberler, P. Hufnagl, B.R. Binder, A.M. Hirschl, and J. Ring Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients FASEB J 12 1998 1559 1569
11. R. Valenta, S. Natter, S. Seiberler, M. Roschanak, N. Mothes, and V. Mahler Autoallergy: a pathogenetic factor in atopic dermatitis? Curr Probl Dermatol 28 1999 45 50
12. M. Hide, T. Tanaka, Y. Yamamura, O. Koro, and S. Yamamoto IgE-mediated hypersensitivity against human sweat antigen in patients with atopic dermatitis Acta Derm Venereol 82 2002 335 340
13. R.A. Krathen, and S. Hsu Failure of omalizumab for treatment of severe adult atopic dermatitis J Am Acad Dermatol 53 2005 338 340
14. J. Corren, D. Diaz-Sanchez, A. Saxon, Y. Deniz, J. Reimann, and D. Sinclair Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis Ann Allergy Asthma Immunol 93 2004 243 248
15. M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hébert, and J. Bousquet Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2003 309 316
16. US Food and Drug Administration. Briefing document on safety. Omalizumab (Xolair) (recombinant humanized monoclonal antibody to IgE) for treatment of allergic asthma. Available from: URL: http://www.fda.gov/cder/foi/label/2003/ omalgen062003LB.pdf. April 18, 2003. Accessed June 19, 2005
17. M.T. Sandstr Targeting immunoglobulin E as a novel treatment for asthma Curr Allergy Asthma Rep 5 2005 109 115
18. R.L. Shields, W.R. Whether, K. Zioncheck, L. O'Connell, B. Fendly, and L.G. Presta Inhibition of allergic reactions with antibodies to IgE Int Arch Allergy Immunol 107 1995 308 312
19. A. Nayak, T. Casale, S.D. Miller, J. Condemi, M. McAlary, and A. Fowler-Taylor Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis Allergy Asthma Proc 24 2003 323 329